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Covalent modiﬁcations of proteins with ubiquitin and ubiquitin-like molecules are instru-
mental to many biological processes. However, identifying the E3 ligase responsible for
these modiﬁcations remains a major bottleneck in ubiquitin research. Here, we present
an E2-thioester-driven identiﬁcation (E2~dID) method for the targeted identiﬁcation of
substrates of speciﬁc E2 and E3 enzyme pairs. E2~dID exploits the central position of
E2-conjugating enzymes in the ubiquitination cascade and provides in vitro generated
biotinylated E2~ubiquitin thioester conjugates as the sole source for ubiquitination in extracts.
This enables puriﬁcation and mass spectrometry-based identiﬁcation of modiﬁed proteins
under stringent conditions independently of the biological source of the extract. We
demonstrate the sensitivity and speciﬁcity of E2-dID by identifying and validating substrates
of APC/C in human cells. Finally, we perform E2~dID with SUMO in S. cerevisiae,
showing that this approach can be easily adapted to other ubiquitin-like modiﬁers and
experimental models.
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B iological repositories such as BioGRID
1 currently list more
than 13,000 posttranslational modiﬁcations with ubiquitin
and ubiquitin-like molecules (UBLs) on proteins encoded
by almost 10,000 genes, indicating that at least half of the proteins
encoded in the human genome are modiﬁed. Because ubiquitin
and UBLs are involved in most cellular processes, it is not sur-
prising that aberrations in ubiquitin and UBL systems have severe
consequences such as neurodegenerative diseases or cancer
formation2,3.
Ubiquitination requires the interplay of three enzymes in a
highly ordered fashion. First, a ubiquitin-activating enzyme (E1)
catalyzes the formation of a ubiquitin thioester on its active
cysteine in an ATP-dependent manner. During the second step,
ubiquitin is transferred to a ubiquitin-conjugating enzyme (E2)
resulting in an E2~ubiquitin thioester (E2~Ub). The E2~Ub
subsequently interacts with a ubiquitin ligase (E3), which pro-
vides the scaffold for substrate recognition4. The majority of E3
ligases contain a really interesting new gene (RING) domain that
catalyzes the transfer of ubiquitin from the E2 directly onto a
lysine residue of the substrate5. In contrast, E3 ligases belonging
to the homologous to E6AP C-terminus (HECT)6 and RING-
between-RING (RBR)7 families initially form an E3~ubiquitin
thioester intermediate on a catalytic cysteine before the substrate
is modiﬁed. Modiﬁcations of substrates with UBLs, such as
SUMO, FAT10, ISG15, NEDD8, or UFM1 require similar enzy-
matic cascades, some of which involve enzymes that can recog-
nize more than one modiﬁer8.
In recent years, advances in mass spectrometry provided not
only comprehensive ubiquitome landscapes9–12, but also
increasingly shed light on proteins modiﬁed by SUMO13,14 and
other less understood UBLs15–19. However, the dynamic and
reversible nature of these modiﬁcations, the weak and/or tran-
sient interaction between ligase and substrate, the signiﬁcant
degree of redundancy and multiplicity between E1, E2, and E3
enzymes, and the rapid destruction of many ubiquitylated pro-
teins still present signiﬁcant technical challenges in identifying E3
ligase substrates20. Current approaches to deﬁne enzyme-
substrate relations include yeast two-hybrid21,22, protein
microarrays23,24, substrate trapping25–28, biotin-dependent
proximity labeling (BioID)29, and engineered ubiquitin enzyme
cascades30. Alternatively, the abundance of modiﬁed substrates
can be increased by overexpressing the E3 ligase of interest31,32.
Given that substrates are targeted for ubiquitin-mediated pro-
teolysis, methods monitoring protein stability in comparison to
known model substrates33 or upon chemical or genetic inter-
ference with E3 ligases have been developed as well34–36. While
each of these approaches has its own strength and weaknesses, we
sought a simple and versatile method that can be applied to
different experimental models without the need for extensive and
time-consuming genetic or protein engineering, and which is
independent of the functional outcome triggered by the mod-
iﬁcation. Here, we demonstrate the speciﬁcity and sensitivity of
E2 thioester-driven substrate identiﬁcation (E2~dID) by identi-
fying and characterizing substrates of the anaphase-promoting
complex/cyclosome (APC/C) in human cells and of the SUMO
E3 ligases Siz1/Siz2 in S. cerevisiae.
Results
Rationale of E2~dID. We reasoned that an afﬁnity labeled
modiﬁer, for example, biotinylated ubiquitin (bioUBB), ligated to
substrates exclusively by the E3 of choice would enable the
straightforward puriﬁcation and identiﬁcation of its speciﬁc
substrates. Further, if the ligation of bioUBB to substrates
occurred in vitro in the context of extracts (in extracto) all
experimental models that support extract preparation including
tissue cell culture, primary cells derived from multicellular model
organisms, and unicellular models, such as yeast, could be used.
The biotin tag allows puriﬁcation of modiﬁed substrates under
denaturing conditions for subsequent identiﬁcation by mass
spectrometry. E2 and E3-speciﬁcity is achieved by chemical
inactivation of endogenous E1 and E2 enzymes within extracts
and quantitative comparison of substrates identiﬁed in the pre-
sence or absence of the E3 ligase of interest (Fig. 1a).
E2~dID with APC/C. As a proof of principle, we set up E2~dID
in HeLa cells and aimed to identify established mitotic substrates
of APC/C. The APC/C is essential for chromosome segregation in
eukaryotic cells by targeting CCNB1 and PTTG1 for proteasomal
degradation. During mitosis and G1 phase, the E2 enzymes
UBE2C and UBE2S are required for initiating and elongating
mainly lysine 11-linked ubiquitin chains on APC/C substrates,
respectively37–39. First, we generated bioUBB by in vitro bioti-
nylation of ubiquitin on a small N-terminal linked AVI-tag40
(Supplementary Figure 1a). Alternatively, bioUBB can be
obtained from commercial sources. To generate E2~bioUBB
thioesters that support APC/C-dependent ubiquitination, we
combined recombinant human E1 (UBA1), E2 (UBE2C),
bioUBB, and ATP in in vitro charging reactions. While
UBE2C~bioUBB thioesters were readily formed, UBE2C became
auto-ubiquitinated during charging as indicated by a mobility
shift of UBE2C on SDS-PAGE that was not sensitive to reduction
with dithiothreitol (DTT) (Supplementary Figure 1b). This might
decrease the sensitivity of E2~dID as auto-ubiquitinated UBE2C
molecules will be puriﬁed and identiﬁed by subsequent mass
spectrometry analysis along with speciﬁc APC/C substrates. To
reduce auto-ubiquitination, we mutated the conserved lysine 119
located in close proximity to the active site cysteine to arginine
(K119R). Indeed, UBE2CK119R exhibited highly reduced auto-
ubiquitination (Supplementary Figure 1c), while almost retaining
its full activity when used with APC/C to ubiquitinate an N-
terminal fragment of CCNB1 (amino acids 1–89) (Supplementary
Fig. 1d).
We initially sought to purify UBE2CK119R~bioUBB thioesters
from charging reactions. However, its short half-life prevented
generating sufﬁcient amounts of pure UBE2CK119R~bioUBB.
Instead, we stopped charging reactions by iodoacetamide (IAA),
which alkylates active site cysteines of E1 and E2 enzymes, but
does not interfere with pre-formed E2~bioUBB linkages.
Importantly, IAA-treated charging reactions supported APC/C-
dependent ubiquitination of PTTG1 in vitro, suggesting that IAA
does not affect APC/C activity (Supplementary Figure 1e). We
also added IAA to anaphase extracts prepared from HeLa cells to
preclude endogenous E1, E2, HECT, and RBR E3 enzymes from
utilizing the supplied recombinant ubiquitin. Adding 5–10 mM
IAA or 50 mM N-ethylmaleinimid (NEM) to extracts was
sufﬁcient to prevent conjugation of ubiquitin to proteins
(Supplementary Figure 1f) and therefore, we used 10 mM IAA
in all subsequent experiments. We decided against NEM because
adding NEM, but not IAA at pH= 7.5 inhibited APC/C in vitro
(Supplementary Figures 1e, g). Notably, the addition of IAA also
inhibits cysteine-containing de-ubiquitinating enzymes and
thereby preserves bioUBB-conjugated substrates. Together, this
ensured that the E2~bioUBB conjugates supplied with IAA-
treated charging reactions act as the exclusive source for bioUBB
that is ligated to the substrate by endogenous RING-type E3
ligases in the extract (Fig. 1b). In addition, we treated extracts
with the proteasome inhibitor MG132 to prevent potential
substrate degradation.
Because many E2 enzymes including UBE2C have been
reported to work together with several E3 ligases41,42, the
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bioUBB-modiﬁed proteins might represent substrates from
multiple E3 ligases. To reveal to which extent bioUBB modiﬁca-
tions depended on APC/C, we performed E2~ID in unperturbed
anaphase extracts (E3 active) and anaphase extracts, where APC/
C has been removed (E3 inactive) by immuno-depleting its
crucial ANAPC4 subunit. ANAPC4 immunoprecipitation also
co-depleted catalytically active subunits ANAPC2, ANAPC11,
and ANAPC10 (Supplementary Figure 2a) and strongly reduced
UBE2CK119R~bioUBB-dependent ubiquitination of proteins
(Fig. 1b) in agreement with the notion that APC/C is the
predominant E3 enzyme that employs UBE2C in mitosis.
Hence, recombinant E2~bioUBB thioesters drive the
ubiquitination of proteins in extracts in presence of an
alkylating reagent that inactivates the endogenous E1 and E2
ubiquitin enzymes. Therefore, E2~bioUBB thioesters act as
the sole source of bioUBB that is conjugated to substrates
enabling their enrichment by afﬁnity puriﬁcation under denatur-
ing conditions.
E2~dID is E2 and E3-speciﬁc. During E2~dID extracts are
supplied with an excess of 24 to 114-fold of recombinant
UBE2CK119R~bioUBB compared to endogenous UBE2C (Sup-
plementary Figure 2b, c). While this should not affect substrate
recognition by E2-compatible E3 ligases, an excess of E2~bioUBB
might facilitate atypical E2/E3 pairings resulting in aberrant
ubiquitination. To test this scenario, we supplied anaphase
extracts with infrared dye-labeled N-terminal CCNB1, either
together with UBE2CK119R~bioUBB or with Skp1 Cullin Fbox
(SCF)-speciﬁc UBE2R1~bioUBB. We found that only
UBE2CK119R~bioUBB supported CCNB1 ubiquitination, but not
UBE2R1~bioUBB nor catalytically inactive UBE2CC114S (Fig. 2a).
Notably, UBE2R1 was active as UBE2R1~bioUBB thioesters were
readily formed (Supplementary Figure 2d) and supported the
conjugation of bioUBB to proteins in extracts treated with IAA
(Supplementary Figure 2e). We also assayed CCNB1 ubiquiti-
nation in the absence of APC/C to exclude that the excess of
UBE2CK119R~bioUBB drives substrate ubiquitination in an E3-
independent manner. This showed that CCNB1 ubiquitination
strictly required APC/C (Fig. 2b), suggesting that E3 speciﬁcity is
retained during E2~dID.
To determine if E2~dID also supports the ubiquitination of
endogenous substrates, we performed E2~dID in mock and
ANAPC4-depleted anaphase extracts and puriﬁed bioUBB-
modiﬁed substrates using NeutrAvidin beads. Western blot
analysis revealed that both, the amount of total ubiquitination
and of endogenous CCNB1 required APC/C (Fig. 2c). Thus,
E2~dID supports the modiﬁcation of endogenous substrates in
IAA-treated cell extracts in an E2/E3-speciﬁc manner.
UBE2C and UBE2R1 are primarily known as APC/C and SCF-
associated E2 enzymes, however other E2’s are more promiscuous
and support ubiquitination by multiple E3 enzymes41. Given that
E3 speciﬁcity is preserved with more promiscuous E2’s, this
might be of advantage for E2~dID as it circumvents the
requirement to know the speciﬁc E2-E3 pairing. We tested this
idea using UBE2D1, which is known to interact with multiple E3
ligases including APC/C37,41,43. Recombinant UBE2D1 readily
produced E2~bioUBB thioesters and in contrast to UBE2C did
not exhibit extensive auto-ubiquitination (Supplementary Fig-
ure 2f). When added to IAA-treated anaphase extracts
UBE2D1~bioUBB thioesters efﬁciently promoted ubiquitination
of proteins (Supplementary Figure 2g). As expected UBE2D1~-
bioUBB-driven ubiquitination was not as sensitive to APC/C
depletion compared to UBE2CK119R ~bioUBB thioesters, reﬂect-
ing its ability to interact with several E3 ligases (compare
Supplementary Figure 2g and Fig. 2c). Nevertheless, ubiquitina-
tion of CCNB1 required APC/C, indicating that during E2~dID
E3 speciﬁcity is retained, even with an E2 enzyme supporting
multiple E3 ligases (Supplementary Figure 2h).
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Fig. 1 Principle of E2~dID. a Schematic representation of the E2~dID technique: (1) In vitro generation of E2~modiﬁer conjugates (charging reaction) using
biotinylated UBB or UBLs. (2) Cell or tissue extracts are treated with the indicated chemicals to inactivate the endogenous cysteine-dependent ubiquitin
and UBL enzymes. To reveal E3-speciﬁc substrates extracts with active E3 (2b) or inactive E3 (2b) are prepared. (3) Charging reaction and extracts are
combined to initiate modiﬁcations in extracto. (4) Modiﬁed proteins are puriﬁed under denaturing conditions through the biotinylated modiﬁer. (5)
Analyses of puriﬁed proteins, e.g. by Western blot or mass spectrometry. b Representative (n= 4) Western blot analysis of E2~dID-dependent labeling of
APC/C substrates in extracts with the indicated antibodies (Supplementary Data 7). Note, that ubiquitination of proteins in the extracts depends on the
presence of E2~bioUBB conjugates (UBE2C) and ANAPC4 in the extract (compare ± APC/C)
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We conclude that even in the presence of an excess of
externally-supplied recombinant E2~bioUBB thioesters E2 and
E3 speciﬁcity is maintained during E2~dID. Since substrate
speciﬁcity depends on the E3 ligase, promiscuous E2-conjugating
enzymes can be employed for E2~dID as long as they can act
together with the E3 of interest.
Deﬁning the mitotic substrates of APC/C by E2~dID. Our
results conﬁrm that E2~dID enables UBE2C and APC/C-speciﬁc
ubiquitination of CCNB1 and PTTG1. To assess the performance
of E2~dID towards all potential APC/C substrates within extracts,
we employed quantitative mass spectrometry based on tandem
mass tag labeling (TMT)44. Brieﬂy, we performed E2~dID
according to Fig. 1a and Fig. 2c, using extracts of cells synchro-
nized in anaphase. We chose mitotic extracts, where APC/C
substrates are particularly well-characterized to aid our evaluation
of the overall sensitivity and speciﬁcity of E2~dID. Notably, we
observed a strong Pearson correlation (R > 0.93) between indivi-
dual repeats in all conditions indicative of high reproducibility
(Supplementary Fig. 3a). To identify APC/C substrates with high
conﬁdence, we accepted only substrates, which exhibited at least a
2-fold (log2= 1) enrichment in UBE2CK119R~bioUBB reactions
compared to control (bioUBB, UBE2CC114S) and ANAPC4-
depleted (−APC/C) samples (Supplementary Data 1). From the
60 hits that satisﬁed these criteria 30 have previously been
reported, while 26 represent thus far uncharacterized candidates
(Fig. 3a and Supplementary Data 2). Except for KATNBL1 and
COBLL1 all uncharacterized candidates were identiﬁed to be
ubiquitinated1 and 69% contain high-ranking predicted APC/C
recognition motifs45 (Supplementary Data 1). The remaining hits
included three APC/C subunits, ANAPC3, ANAPC8, ANAPC13,
and the APC/C inhibitor FBXO5. The fact that veriﬁed APC/C
substrates including PLK1, KIF2C, and ANLN were enriched
compared to –APC/C samples, but remained below our threshold
(1.75, 1.70, and 1.39-fold enrichment, respectively) suggests that
our dataset contains additional candidates (Supplementary
Data 1).
To evaluate the performance of E2~dID in identifying bonaﬁde
APC/C substrates, we generated a curated list of 53 well-
characterized human and murine mitotic substrates with
experimentally-veriﬁed APC/C recognition motifs (D box, KEN
box, IR/LR tail, ABBA motif)(Supplementary Data 2). Next, we
compared E2~dID to three alternative approaches mainly
focusing on identifying APC/C substrates during mitosis. First,
to co-regulation proteomics, an approach that monitors changes
of protein abundance during mitosis by TMT mass spectrometry
assuming that candidate substrates share a similar abundance
proﬁle with model APC/C substrates33. Second, to a mitotic exit
ubiquitome based on proteomic snapshots of prometaphase, early
and late anaphase cells containing in vivo biotinylated proteins46.
Third, to antibody-based detection of protein arrays that were
incubated with mitotic extracts supplied with an excess of
recombinant UBA1, UBE2C, and ubiquitin23. Despite suggesting
the lowest number of candidates, E2~dID performed best and
identiﬁed 51% of reference substrates, followed by 34% for the
mitotic exit ubiquitome, 32% for co-regulation proteomics, and
21% for protein arrays, respectively (Supplementary Fig. 3b).
Notably, with the exception of PLK1, BUB1, and 6 late mitotic
exit substrates, which might not yet be targeted by APC/C in the
anaphase extracts we used, E2~dID captured the entire set of
substrates suggested by the three alternative approaches together
(Supplementary Data 2).
Together, this validates E2~dID as a powerful method to
identify substrates of E3 ligases based on extracts that can be
easily prepared. E2~dID reveals more than half of a reference list
containing well-characterized mitotic APC/C substrates and
thereby compares well to existing alternative approaches.
E2~dID candidates are ubiquitinated in vivo. During E2~dID
ubiquitination of proteins occurs in extracts. To assess if sub-
strates suggested by E2~dID are also ubiquitinated by APC/C in
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living cells, we performed quantitative diGly proteomics com-
paring the mitotic ubiquitinome in the presence and absence of
APC/C activity (Fig. 3b). To rapidly inactivate APC/C during
mitosis in living cells, we took advantage of auxin-mediated
degradation in animal cells47,48 and the auxin-dependent nano-
body mAID-vhhGFP, which targets proteins fused to GFP and
GFP-like proteins such as Venus49. Adding the synthetic auxin
analog 1-naphthaleneacetic acid (NAA) for three hours to
prometaphase-arrested cells enabled mAID-vhhGFP to decrease
the levels of endogenous 3xFlag-Streptavidin-binding-peptide-
Venus-ANAPC449 by ~75% (Fig. 3c, d). We have previously
shown that this degree of ANAPC4 depletion is sufﬁcient to
arrest cells in mitosis and to prevent the destruction of cyclins
CCNA2 and CCNB149. Finally, to allow cells proceeding to an
anaphase-like state in absence of APC/C activity and protein
degradation, we added 10 µM MG132 and 9 µM of the CDK1
inhibitor RO3306 to force mitotic exit (Fig. 3b, see methods).
Quantitative mass spectrometry analyses of +ANAPC4 and
– ANAPC4 extracts including diGly-enrichment and TMT-
labeling identiﬁed more than 18,000 peptides with a diGly
signature. 268 peptides were assigned to 38/53 (~ 72%) proteins
of curated mitotic APC/C substrates (see above), whereas 260
peptides mapped to 65% (39/60) of candidates suggested by
E2~dID (Supplementary Data 3). Notably, the abundance of
ubiquitinated peptides of curated substrates and E2~dID
candidates were sensitive to ANAPC4 depletion. In contrast,
the total mitotic ubiquitinome reﬂecting substrates of all E3
ligases remained largely unaffected by APC/C inactivation
(Fig. 3e).
We conclude that candidate APC/C substrates predicted by
E2~dID in vitro are also substrates of APC/C in living cells. Thus,
even though E2~dID is performed in vitro its substrate speciﬁcity
largely recapitulates the situation in vivo.
Functional analyses of E2~dID candidates in vivo. E2~dID
suggested a high number of candidates that have not been linked
to APC/C previously. We selected six substrates covering high
(LSM14B and SGO2; 6.61 and 6.11-fold enrichment), medium
(ESPL1, NF2, and UPF3B; 5.27, 5.0, and 4.93) and lower
(DEPDC1; 2.30) enrichment scores (Supplementary Data 1) for
further validation. Whereas ESPL1 is crucial for mitosis and
meiosis50–52, the functions of SGO2 in somatic tissues remain
largely unexplored53. DEPDC1 regulates mitotic progression54
and NF2 associates with the mitotic spindle55. Together, these
candidates appear to fulﬁll functions in mitosis or meiosis that are
typically regulated by APC/C. In contrast, LSM14B and UPF3B
have been linked to mRNA turnover, in particular to the CCR4-
NOT deadenylase complex56 and nonsense-mediated mRNA
decay57—roles the APC/C has not been implicated in thus far.
During mitosis, APC/C ubiquitinates its substrates in an
ordered fashion resulting in proteolysis by the 26S proteasome.
Thus, we ﬁrst monitored the stability of selected candidates
during mitotic exit by releasing cells from a taxol-induced
prometaphase arrest in the presence of the AURKB inhibitor
ZM447439 to increase synchronicity within the cell population
(see Methods). The levels of SGO2 decreased early during the
release and before the anaphase APC/C substrate AURKB58,59. In
contrast, we did not observe a detectable decrease of LSM14B,
UPF3B, and NF2 proteins. Full-length ESPL1 decreased after 30
min resulting in a ~ 170 kDa N-terminal (ESPL1N−term) and a ~
60 kDa C-terminal polypeptide (ESPL1CC−term), reﬂecting ESPL1
activation and auto-cleavage once CCNB1 and PTTG1 are
degraded. Subsequently, the levels of ESPL1N−term decreased
slightly towards the end of the release (105 and 120 min), whereas
ESPL1CC−term remained largely stable (Fig. 4a). The lack of
available antibodies precluded us from assessing the stability of
DEPDC1. Nevertheless, during the preparation of this manu-
script, DEPDC1 was identiﬁed as an APC/CFZR1 substrate that is
degraded during mitotic exit in a D box-dependent manner60.
If the decrease of SGO2 and ESPL1 depended on APC/C, then
ubiquitination of both candidates should be sensitive to APC/C
interference. Therefore, we extracted their ubiquitination state in
the presence and absence of APC/C activity from the mitotic
diGly ubiquitinome (Fig. 3e). In agreement with APC/C-
dependent degradation, the abundances of diGly-linked peptides
of SGO2, DEPDC1, and to a lesser extent of ESPL1 were sensitive
to ANAPC4 depletion. In contrast, diGly peptides of LSM14B,
UPF3B, and NF2 were unaffected (Fig. 4b). To conﬁrm that
SGO2 and ESPL1N−term are targeted for destruction by APC/C,
we depleted 3xFlag-Streptavidin-binding-peptide-Venus-
ANAPC4 with mAID-vhhGFP4 during prometaphase and
monitored their stability during a RO3306-induced mitotic
override with or without MG132 (Fig. 3b). Depleting ANAPC4
or inhibiting the proteasome stabilized SGO2 similar to CCNB1
or AURKB indicative of APC/C-dependent proteolysis. While
ANAPC4 depletion and MG132 treatment delayed ESPL1 auto-
cleavage, we did not observe a clear stabilization of ESPL1N−term
(Fig. 4c). However, the interpretation of this result is complicated
by the observation that ANAPC4 depletion delayed ESPL1 auto-
cleavage and thus the generation of ESPL1N−term. To conﬁrm
SGO2 and ESPL1 as substrates, we assessed their binding to APC/
C in interphase (G2 phase) and mitosis (prometaphase). Indeed,
SGO2 and ESPL1 predominately co-precipitated with ANAPC3
in mitosis (Fig. 4d). We determined the cell cycle stage of this
interaction in more detail by synchronizing HeLa cells into all cell
cycle phases (see Methods). Western blotting for cell cycle
markers CCNB1 (present in HeLa cells in G2, PM, A, and S),
CCNA2 (G2 and S) and CDT1 (PM, A, and G1) conﬁrmed the
identity of individual cell cycle stages (Supplementary Fig. 4a).
Immunoprecipitating ANAPC3 with a different anti-ANAPC3
antibody indicated that SGO2 and ESPL1 predominately co-
precipitated with ANAPC3 from prometaphase to anaphase, thus
reﬂecting the timing of their ubiquitination (Supplementary
Fig. 4b).
Fig. 3 Performance of E2~dID with ubiquitin and APC/C. a Heat map showing scaled TMT abundances of two independent E2~dID experiments with
bioUBB and APC/C performed as shown in Fig. 2c. Only substrates that displayed an at least 2-fold enrichment (E2~bioUBB/– APC/C > 2) are indicated by
gene names and are ordered from top to bottom with decreasing enrichment. Italics, known APC/C substrates; underlined, APC/C subunits and regulatory
interactors; bold, candidate substrates revealed by E2~dID; asterisks mark candidates selected for further validation. b Schematic representation of cell
synchronization, APC/C inactivation and sample preparation for diGly MS/MS. (c) Representative Western blot (n= 3) of cell extracts prepared
from − NAA treated (+ANAPC4) and + NAA treated (− ANAPC4) cells. d Quantiﬁcation of the data shown in (c). Bars indicate the mean ± s.e.m. of
three independent experiments. e Box plot analysis of three independent diGly MS/MS experiments, showing changes in the abundance of ubiquitinated
peptides in the presence or absence of APC/C of the total ubiquitinome (left), E2~dID candidates (middle) and curated APC/C substrates (right). Box plots
show the median, ﬁrst and third quartiles and whiskers extend to the smallest or the largest value no more than 1.5-fold of the inter-quartile range.
Signiﬁcance according to the Wilcoxon rank sum test
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Fig. 4 Functional validation of APC/C substrates identiﬁed by E2~dID. a Representative Western blot analysis (n= 2) of mitotic release samples using the
indicated antibodies. HeLa cells were synchronized in prometaphase with 245 nm taxol (see Methods), collected by mitotic shake-off, washed and released
into fresh media containing 10 µm ZM447439. The time-depended decrease in the levels of mitotic markers H3 (pS10), APC/C substrates PTTG1, CCNB1,
and AURKB indicate APC/C activation. Arrows indicate phosphorylated ANAPC3. b Scatter plot showing the fold-change in lysine ubiquitination in
response to ANAPC4 depletion for early APC/C substrates and E2~dID candidates selected for further analyses. Each “K” represents the fold-change
(log2) of a ubiquitinated peptide identiﬁed from the indicated proteins. The color gradient from blue (no change) to red (negative change) illustrates the
fold-change in the abundance of identiﬁed ubiquitinated peptides. c Representative Western blot analysis (n= 2) of a mitotic release for the indicated
time-points in the presence (+ANAPC4) and absence (− ANAPC4) of APC/C activity as described in Fig. 3b, but without the addition of MG132. Note,
inhibiting CDK1 by RO3306 is required to allow mitotic exit in absence of CCNB1 ubiquitination and degradation. Quantiﬁcation of CCNB1, AURKB, and
SGO2 levels present the mean ± s.e.m. from two independent experiments with each three technical replicates. d Representative Western blot analysis
(n= 3) of control and ANAPC3 immunoprecipitations from G2-phase (G2) and prometaphase (PM)- synchronized cell extracts showing the interaction of
SGO2 and ESPL1 with APC/C. Arrows indicate phosphorylated ANAPC3, while the lower band is derived from prior ANAPC4 detection
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Taken together our data suggest that from the selected
candidates at least ESPL1, DEPDC1, and SGO2 are ubiquitinated
by APC/C in vivo and that ESPL1 and SGO2 interact with APC/C
in mitosis. While ubiquitination targets SGO2 and DEPDC160
for destruction, its effect on ESPL1N−term needs further
investigation.
APC/C ubiquitinates UPF3B, LSM14B, DEPDC1, and NF2
in vitro. Thus far our experiments in living cells do not provide
evidence that LSM14B, UPF3B, and NF2 are bonaﬁde APC/C
substrates. Therefore, we attempted to validate UPF3B, LSM14B,
and NF2 as APC/C substrates in vitro using a combination of in
extracto and APC/C activity assays based on recombinant com-
ponents. First, we investigated if E2~dID reactions can reveal the
covalent attachment of one or more ubiquitin molecules to
LSM14B, UPF3B, and NF2. The anaphase extracts used for
E2~dID contain APC/C activated by both, CDC20 and FZR1. To
uncover a preference for either co-activator we prepared extracts
enriched for APC/CCDC20 and APC/CFZR1 (Supplementary Fig-
ure 5a), addedS35-labeled in vitro-translated candidates or
PTTG1 as a positive control (Fig. 5a), and performed E2~dID.
Puriﬁcation of bioUBB-linked proteins and analyses by auto-
radiography indicated that PTTG1 and NF2 were preferred
APC/CCDC20 substrates, whereas LSM14B displayed a preference
for APC/CFZR1. In contrast, DEPDC1 and UPF3B were ubiqui-
tinated to an equivalent extent by both co-activators (Fig. 5b).
To conﬁrm that their modiﬁcation with bioUBB required APC/C,
we repeated E2~dID for each candidate in context of the pre-
ferred co-activator in mock or ANAPC4-depleted extracts.
Except for NF2, candidate ubiquitination absolutely depended
on APC/C (Supplementary Figure 5b). NF2 ubiquitination was
also sensitive to APC/C depletion, but was not completely
abolished as in case of the other candidates. This residual NF2
ubiquitination may be due to a small (undetectable by Western
blot) remainder of APC/C present upon depletion or another
E3 ligase working together with UBE2C~bioUBB.
In dividing cells APC/C employs UBE2C as an initiating
and UBE2S as a chain-elongating enzyme to assemble lysine
11-linked ubiquitin chains on its substrates37,38. However, during
E2~dID the IAA-dependent inactivation of all cysteine-
containing enzymes prevents chain elongation by endogenous
UBE2S. We therefore tested if ubiquitin chains on UPF3B and
LSM14B initiated by UBE2C can be elongated by UBE2S in
in vitro APC/C activity assays based on puriﬁed components.
Indeed, the addition of UBE2S triggered poly-ubiquitination of
UPF3B (Fig. 5c) and LSM14B (Fig. 5d), as it does for well-
characterized APC/C substrates (Supplementary Fig. 3c)37.
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Fig. 5 UPF3B and LSM14B are substrates of APC/C in vitro. a Representative (n= 7) autoradiography of methionine S35-labelled APC/C candidate
substrates used for subsequent E2~dID experiments expressed by coupled in vitro transcription/translation in reticulocytes. b Representative (n= 4)
autoradiography of NeutrAvidin-puriﬁed proteins from of E2~dID reactions using CDC20 or FZR1-enriched extracts (see Supplementary Fig. 5a) containing
active UBE2CK119R or inactive UBE2CC114S as well as radiolabeled candidates shown in a. Arrowheads indicate bioUBB-modiﬁed substrates and asterisks
co-puriﬁed unmodiﬁed substrates. c Representative Western blot analysis (n= 3) of an in vitro APC/C activity assay with puriﬁed components using strep
II-tagged UPF3B as a substrate. d Representative Western blot analysis (n= 3) as in c using strep II-tagged LSM14B as a substrate. Note, the addition of
ubiquitin chain-elongating UBE2S results in higher molecular weight polyubiquitinated species of UPF3B and LSM14B
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Next, we sought to identify the destruction degrons in UPF3B and
LSM14B that are recognized by APC/C. Bioinformatic degron
prediction45 suggested three D boxes and one conserved KEN box
as likely candidates for UPF3B (Supplementary Figure 5c, d). We
recombinantly expressed variants of UPF3B mutated in each of
the three predicted degrons and assessed their abilities to be
ubiquitinated by APC/C in vitro. Mutation of the KEN box
almost completely abolished UPF3B ubiquitination, whereas
mutating either of the D boxes did not have a substantial effect
(Supplementary Fig. 5e). LSM14B APC/C-degron prediction
identiﬁed three conserved motifs within 54 central amino acids
of the LSM14B polypeptide: a D box, a classical KEN box and a
DEN motif, which acts as a KEN box in S. cerevisiae CDC20 and
A. thaliana PATRONUS during meiosis61,62 (Supplementary
Figure 5f, g). Mutagenesis of the KEN box alone or together with
the D box had no effect, whereas combining KEN and DEN
mutations prevented LSM14B ubiquitination (Supplementary
Figure 5h).
We conclude that in vitro UPF3B, LSM14B, DEPDC1, and
NF2 are substrates of APC/C, and like most characterized
substrates these can be targeted by APC/CCDC20 and/or APC/
CFZR1. UPF3B and LSM14B ubiquitination is increased by UBE2S
and requires KEN motifs as it the case of several APC/C
substrates.
SUMO E2~dID reveals substrates of Siz1/Siz2 in S. cerevisiae.
Since other UBLs including SUMO employ similar enzymatic
cascades to modify substrates, E2~dID should in principle be
applicable to all UBLs that are ligated by E3 enzymes that do not
require active site cysteines. Additionally, E2~dID should be
independent of the experimental model system as long as cell
extracts can be obtained. To test these ideas, we applied E2~dID
to wild type and siz1Δsiz2Δ S. cerevisiae strains and attempted
deﬁning substrates of Siz1 and Siz2 SUMO (Smt3) ligases using
Ubc9 as the E2-conjugating enzyme charged with biotinylated
Smt3. During E2~dID with APC/C, we noticed that the two
negative controls, bioUBB and UBE2CC114S, were highly corre-
lative across experiments (at least R > 0.93) (Supplementary
Fig. 3c). Therefore, to simplify the workﬂow of E2~dID, we
omitted the catalytically inactive E2 control and processed only
bioSmt3, Ubc9~bioSmt3 and siz1Δsiz2Δ samples for quantitative
mass spectrometry. Similar to E2~dID with ubiquitin and APC/C,
we observed a strong correlation (at least R > 0.91) between
individual repeats and different conditions (Supplementary
Fig. 3d). The data were processed as before with the exception
that we lowered the threshold for Siz1/Siz2 speciﬁcity to 1.41-fold
(log2= 0.5) (Supplementary Data 4). This accounts for the
observation that in yeast Ubc9 can directly modify substrates
without the associated E363 resulting in partially overlapping
substrates.
In total, our study yielded 34 hits that were sensitive to Siz1/
Siz2 deletion (Fig. 6a). While more than half (20/34) of identiﬁed
candidates have been reported to be SUMOylated1 (Supplemen-
tary Data 5) only PCNA (Pol30)64, septin (Cdc3)65,66, topoi-
somerase 1 (Top1)67, topoisomerase 2 (Top2)67,68 and RNA
polymerase (Rpo21)69 were previously characterized as Siz1/Siz2-
speciﬁc substrates (Supplementary Data 5). Thus, investigating
the role of SUMOylation of the other candidates might
signiﬁcantly expand our knowledge of Siz1/Siz2 function in yeast.
Taken together, the successful application of E2~dID with
ubiquitin and SUMO in human and yeast cells illustrates the
sensitivity and versatility of E2~dID and suggests that this
approach can be readily extended to other UBLs and experi-
mental models.
Def1 is SUMOylated in a Siz1/Siz2-speciﬁc manner. To inves-
tigate whether E2~dID using Ubc9~bioSmt3 in yeast also sug-
gested Siz1/Siz2 substrates with high conﬁdence we selected the
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Fig. 6 E2~dID with SUMO and Siz1/Siz2 in S. cerevisiae. a Heat map showing scaled TMT abundances of two independent E2~dID experiments with bioSmt3
and Siz1/Siz2 comparing bioSmt3 with Ubc9~bioSmt3 in wild type and siz1Δsiz2Δ extracts. Only substrates that displayed an at least 1.41-fold increase
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b Representative Western blot (n= 3) analysis of HA immunoprecipitates from WT and Δsiz1Δsiz2 strains expressing HA-tagged Def1 protein from its
endogenous locus
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lower enriched substrate Def1 (1.65-fold enrichment) for further
analysis. Def1 acts as a RNA Polymerase II degradation factor
during the DNA damage response70. We expressed HA-tagged
Def1 from its genetic locus in wild type and siz1Δsiz2Δ cells,
immunoprecipitated the protein from yeast extracts using an
antibody against the HA-tag and analyzed its SUMOylation state
by anti-Smt3 Western blot. Indeed, precipitates of Def1 were
positive for Smt3 in a Siz1/Siz2-dependent manner indicating that
it is a Siz1/Siz2 substrate in vivo (Fig. 6b).
Thus, as observed for ubiquitin and APC/C in human cells,
E2~dID with Smt3 and Siz1/Siz2 in yeast performs well in
identifying E3 substrates.
Discussion
Identifying substrates of speciﬁc E3 ligases remains a major
challenge in ubiquitin and UBL biology. Here, we present E2~dID
as a versatile and straightforward approach to directly link ubi-
quitin or UBL-modiﬁed substrates to the responsible E2/E3
enzyme pair in a highly sensitive and speciﬁc manner. E2~dID
relies on cell extracts (Fig. 1) and thus is applicable to any bio-
logical source, where sufﬁcient material can be provided. Extracts
contain only soluble proteins and may not recapitulate all
features required for faithful substrate recognition by E3 ligases,
e.g. the contribution of spatial regulation. Nevertheless, key
characteristics of the source material such as a particular cell
cycle phase, a differentiation stage or tissue-speciﬁcity are
retained in extracts and will contribute to E3 selectivity and
speciﬁcity. Indeed, mitotic APC/C substrates suggested by
E2~dID in vitro largely overlap with APC/C substrates identiﬁed
by diGly proteomics in living cells (Fig. 3). Due to the alkylation
step E2~dID is only compatible with E3 ligases that do not
contain active site cysteines such RING ligases, the by far
largest class of E3 enzymes. However, if HECT~UBB, HEC-
T~ISG15, or RBR~UBB conjugates can be produced in vitro,
the principle of E2~dID can be readily be extended to these ligase
families as well.
Because biotinylated modiﬁers are provided as in vitro gener-
ated E2~modiﬁer conjugates (Fig. 2), there is no need for time-
consuming genetic or protein engineering of the source material,
which is required for biotinylation approaches in living cells46,71
or for engineered E1-E2-E3 cascades30. Since most E1 and E2
enzymes as well as ubiquitin and UBLs are commercially available
or can be easily expressed in E. coli, performing E2~dID does not
require extensive biochemical expertize. A potential caveat of
recombinant E2’s, ubiquitin and UBLs is their lack of post-
translational modiﬁcations that might contribute to function72–74.
Nevertheless, it is possible that extracts are capable of correctly
modifying the supplied recombinant proteins as they are also able
to drive ubiquitination using the in the extract contained E3
enzymes.
For increased speciﬁcity, E2~dID requires the inactivation of
endogenous ubiquitin enzymes, this can be achieved chemically
by cysteine alkylation. Here, we have used IAA because in vitro
APC/C appears to be sensitive to NEM-treatment (Supplemen-
tary Figure 1). IAA can produce lysine adducts that mimic the
ubiquitin signature diglycine tag75. This is not an issue in the
context of TMT labeling experiments because after trypsin
digestion the remnant diGly modiﬁcation contains a primary
amine that will react with the TMT label, thus leading to a mass
shift that is very different from the mass of lysine adducts.
Nevertheless, in other experimental workﬂows alternative alky-
lating reagents such as chloroacetamide or bromoacetamide
should be considered to avoid misidentiﬁcation of ubiquitin sites.
To increase speciﬁcity further, a way to interfere with E3 function
is required. Here, we have used antibody-based depletion, auxin-
mediated protein degradation or genetic deletion to interfere with
APC/C and Siz1/Siz2, respectively. In addition, the increasing
number of small molecule inhibitors targeting ubiquitin and UBL
ligases provide attractive alternatives. As substrate speciﬁcity
depends on E3 ligases, also E2 enzymes that interact with several
E3’s can be employed for E2~dID, when a quantitative mass
spectrometry approach is employed to reveal only substrates of
the E3 of interest. We highlight this notion by demonstrating that
CCNB1 ubiquitination through UBE2D1~bioUBB thioesters
requires APC/C (Supplementary Figure 2), even though UBE2D1
has been suggested to work in addition with at least 15 other E3
ligases41.
Modiﬁcation of proteins with ubiquitin or UBLs by endogen-
ous E3 ligases in extracto has previously been applied to sub-
strates immobilized on microarrays23,24. However, key differences
distinguish these approaches from E2~dID and potentially
explain its increased sensitivity in identifying reference APC/C
substrates (51% versus 21% or 6%, Supplementary Data 2), and
its higher speciﬁcity: 45% (27/60) of all candidates suggested by
E2~dID contain experimentally validated APC/C recognition
degrons45 compared to only 9% (11/128)23 or 2% (3/149)24 of
candidates suggested by microarrays. E2~dID takes advantage of
endogenous proteins in extracts and is therefore limited primarily
by the extent of ubiquitination that can be achieved by the
E2~bioUBB conjugate. In contrast, microarrays are limited by the
number of immobilized proteins, may sterically occlude the
interaction with E3 enzymes, and the recombinant proteins lack
native posttranslational modiﬁcations that may be required for
substrate recognition. Lastly, denaturing washes as employed
during E2~dID are required to ensure that only directly modiﬁed
proteins, but not their modiﬁed interactors are identiﬁed.
Based on the number of identiﬁed reference substrates E2~dID
performs also well in predicting bonaﬁde APC/C substrates com-
pared to recent indirect approaches, such as the mitotic exit ubi-
quitome46 or co-regulation proteomics33. While our study certainly
beneﬁted from the ever-increasing sensitivity in mass spectrometry,
this is not surprising since both approaches solely depend on the
activity proﬁle of APC/C during mitosis to enrich for its substrates.
Further, methods that depend on changes in substrate turnover
upon interference with E3 ligases of interest33–36 are only suitable to
identify substrates that are targeted for degradation, whereas
E2~dID is also compatible with non-degradative modiﬁcations.
We provide evidence that six E2~dID-suggested substrates
spanning the whole range of our candidate ranking are substrates
of APC/C. Ubiquitination of SGO2, DEPDC1, and ESPL1 during
mitosis depend on APC/C in vivo (Fig. 4). Indeed, SGO2 and
DEPDC1 are destroyed by ubiquitin-mediated proteolysis during
mitotic exit, thereby fulﬁlling key characteristics of typical APC/C
substrates (Fig. 4 and60). We ﬁnd that ESPL1 and SGO2 pre-
dominately interact with mitotic but not interphase APC/C
(Supplementary Figure 4), however unlike for SGO2 we ﬁnd no
evidence that the levels of ESPL1 are sensitive to APC/C inhibi-
tion. We note, however, that during G1 phase the levels of full-
length ESPL1 and ESPL1N−term are considerably reduced com-
pared to mitosis (Supplementary Figure 4a) suggesting that
ESPL1 degradation might occur at a later time-point. APC/C
inactivation partially stabilized full-length ESPL1 and delayed the
emergence of ESPL1N−term and ESPL1C−term polypeptides
(Fig. 4c), presumably because binding of CCNB1 and PTTG1 to
ESPL1 hinders its activation even when CDK1 is inhibited.
Alternatively, ubiquitination of ESPL1 by APC/C might directly
contribute to ESPL1 activation. While we do not ﬁnd evidence
that UPF3B, LSM14B, and NF2 are substrates of APC/C in vivo,
at least UPF3B and LSM14B are ubiquitinated by APC/C in vitro,
both during in extracto reactions and APC/C activity assays
(Fig. 5), and their ubiquitin chains are elongated by UBE2S.
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Further, UPF3B and LSM14B ubiquitination requires conserved
KEN boxes indicative of bonaﬁde APC/C substrates (Supple-
mentary Figure 5). Hence, why is UPF3B, LSM14B and NF2
ubiquitination not sensitive to ANAPC4 depletion or results in
degradation? A likely answer is that the diGly proteomics
experiment only provides a snapshot of mitosis during which not
all substrates are targeted by APC/C. Indeed, ubiquitination of
well-characterized anaphase APC/C substrates AURKA and
AURKB was only mildly or not affected by APC/C inactivation,
contrary to substrates that are degraded earlier such as CCNB1,
PLK1, and CENPF (Fig. 4b). Thus, the mitotic time recapitulated
by the diGLy ubiquitinome (Supplementary Data 3) presumably
reﬂects early anaphase and therefore cannot reveal APC/C-
dependent ubiquitination at later stages of mitosis or during G1
phase. Similarly, the time covered by mitotic release experiments
might not be sufﬁcient to reveal changes in the overall protein
levels of UPF3B, LSM14B, or NF2. Nevertheless, it is possible that
the degree of ANAPC4 depletion is insufﬁcient to stabilize pre-
dominately APC/CFZR1 substrates that are ubiquitinated towards
the end of mitosis or that ubiquitination of UPF3B, LSM14B, and
NF2 fulﬁlls non-proteolytic functions.
Compared to ubiquitin E2~dID with APC/C in human cell
extracts, SUMO E2~dID with Siz1/Siz2 in S. cerevisiae extracts
was less sensitive (11%) and speciﬁc (18%) in revealing experi-
mentally validated substrates (Supplementary Data 5). We spec-
ulate this reﬂects the ability of Ubc9 to directly SUMOylate
substrates without an E3 ligase, albeit with a comparably reduced
efﬁciency63. Nevertheless, we show that SUMOylation of Def1
depends on Siz1 and/or Siz2 (Fig. 6), suggesting that the dataset
we present here likely contains additional, thus far uncharacter-
ized Siz1/Siz2 substrates.
In summary, E2~dID is a simple, robust and sensitive method
for identifying substrates of speciﬁc E3 ligases. Based on the
conserved enzymology E2~dID is compatible with all UBLs using
RING-type E3 ligases and thus should be applicable to a multi-
tude of experimental systems. The functions mediated by ubi-
quitin and UBLs are essential to any higher organism and
aberrations in the interplay between E2/E3 enzymes and their
substrates are tightly connected to disease. Hence, E2~dID does
not only bear the potential to provide new insights into funda-
mental cell biological processes, but by virtue of establishing
enzyme-substrate relationships may also provide new targets
within ubiquitin and UBL systems for therapy.
Methods
Molecular cloning. Constructs for bacterial and mammalian expression were
generated by standard molecular biological techniques using the templates, primers
and restriction sites indicated in Supplementary Data 6. Inserts of all constructs
were veriﬁed by sequencing.
Cell culture and cell synchronization. Cell lines were cultured according to
standard mammalian tissue culture protocol and sterile technique at 37 °C in 5%
CO2 and tested in regular intervals for mycoplasma contamination. hTERT RPE-1,
HeLa K, and HeLa FRT/TO-3xFlag-FZR1ala cells were a kind gift from Jonathon
Pines (ICR, London, UK). HeLa FRT/TO-3xFlag-Venus-SBP-ANAPC4+ TIR1+
mAID-vhhGFP4 cells were described previously49. hTERT RPE-1 cells were cul-
tured in DMEM/F12 (Sigma Aldrich) supplemented with 10% (v/v) FBS (Gibco),
1% (v/v) penicillin–streptomycin (Sigma-Aldrich), 1% (v/v) Glutamax (Gibco), 0.5
μg/mL Amphotericin B (Sigma-Aldrich) and sodium bicarbonate (Sigma-Aldrich).
HeLa cells were maintained in Advanced DMEM (Gibco) with
penicillin–streptomycin (Sigma-Aldrich), Glutamax (Gibco), amphotericin B
(Sigma-Aldrich) and supplemented with 2% FBS (Gibco) (HeLa K) or 2% tetra-
cycline free FBS (Gibco) with 200 µg/ml hygromycin for HeLa FRT/TO-3xFlag-
FZR1ala cells or 0.5 µg/ml puromycin and 400 µg/ml neomycin for HeLa FRT/TO-
3xFlag-Venus-SBP-ANAPC4+ TIR1+mAID-vhhGFP4 cells.
To obtain mitotic cells extracts HeLa K cells where pre-synchronized at the
border of G1 to S-phase by standard single (24 h thymidine) or double thymidine
(1st block 19 h, 2nd block 16 h) blocks with 2.5 mM thymidine (Sigma-Aldrich).
Then, cells were washed and released into fresh media containing 245 nM taxol
(Sigma-Aldrich) or 300 nM nocodazole (Sigma-Aldrich) for 9–15 h until 90–95%
of the cells were arrested in prometaphase due to the action of the spindle assembly
checkpoint (SAC). Prometaphase cells were directly harvested by mitotic shake-off.
For metaphase (CDC20-enriched cells), prometaphase cells were collected by
mitotic shake-off, washed in PBS, re-suspended in media containing 10 µM MG132
(Sigma-Aldrich) and 10 µM reversine (Sigma-Aldrich), and incubated for 60 min
on 37 °C to reach metaphase. The addition of reversine inhibits the mitotic
checkpoint kinase MPS1 and immediately shuts down the SAC resulting in APC/
CCDC20 that is free of SAC proteins MAD2L1, BUB1B, and BUB376. For anaphase,
prometaphase cells were collected by mitotic shake-off, washed in PBS, re-
suspended in media containing 10 µM ZM 447439 (VWR) to inhibit the
microtubule tension-sensing arm of the SAC77, and incubated for 30 min at 37 °C
to reach anaphase. To obtain G2- and G1-enriched populations, cells were grown
until 50% conﬂuency, pre-synchronized with a double thymidine block (see above),
released into fresh media, and collected after 5 h (G2 phase) or 18 h (G1-phase). To
obtain extracts enriched for FZR1, HeLa FRT/TO cells were induced to overexpress
FZR1ala with 2.5 mM tetracycline (Sigma-Aldrich) for 24 h and harvested by
trypsinization. Non-phosphorylatable FZR1-expressing cells arrest in interphase
since persistent APC/C activation by FZR1 prevents the accumulation of CCNA2
and CCNB1 and thus prevents mitotic entry.
For diGLy proteomics and mitotic releases in the absence of APC/C activity,
HeLa FRT/TO-3xFlag-Venus-SBP-ANAPC4+ TIR1+mAID-vhhGFP4 cells were
released from a single thymidine block (see above) into fresh media containing 245
nM taxol for a total of 13 h. After 10 h, half of the dishes were supplied with 500
µM 2-naphthoxyacetic acid (NAA, Sigma-Aldrich) for the last 3 h to induce
ANAPC4 degradation. Note, in HeLa FRT/TO cells the residual expression of the
mAID-vhhGFP4 in standard FBS is sufﬁcient to induce ANAPC4 degradation.
Following NAA treatment both, treated (- ANAPC4) and non-treated (+
ANAPC4) prometaphase cells were collected by mitotic shake-off, washed, re-
suspended in fresh media containing 10 µM MG132 and incubated at 37 °C for 30
min to inhibit the proteasome and stabilize ubiquitinated proteins. Subsequently, 9
µM RO-3306 (Sigma-Aldrich) was added for 45 min to induce mitotic exit in the
absence APC/C activity and protein degradation. For the mitotic release
experiments shown in Fig. 4, no MG132 was added to be able detecting protein
degradation and cells were directly lysed in LDS-sample buffer (Thermo-Fisher). In
all other cases cells were washed with PBS, pelleted by centrifugation and ﬂash-
frozen in liquid nitrogen for later extract preparation.
Extract preparation. For extract preparation for E2~dID, cell pellets were re-
suspended in 4 ml MEB buffer (30 mM HEPES-NaOH pH= 7.5, 175 mM NaCl,
2.5 mM MgCl2, 1 mM DTT, 10% Glycerol), supplied with 10 µM microcystin
(Sigma-Aldrich), 1 mM phenylmethylsulfonyl ﬂuoride (PMSF, Sigma-Aldrich),
complete protease inhibitors (Roche) and broken up by nitrogen cavitation78 in a
4639 Cell Disruption Vessel (Parr Instrument Company). For immunoprecipita-
tion (IP), cell pellets were re-suspended in 1.5 × volume MEB buffer containing
0.25% NP40, supplied with 1 mM PMSF, complete protease inhibitors (Roche),
PhosSTOP phosphatase inhibitors (Roche) and incubated on ice for 20 min.
Cleared extracts (16,000 × g, 15 min at 4 °C) were stored at −80 °C for up to
2 months. Before in extracto ubiquitination or E2~dID assays, cell extracts were
supplied with 10 µM MG132 and 10 mM IAA (Sigma-Aldrich) for 2 h at 4 °C.
Protein expression and puriﬁcation. For cell-free protein expression of PTTG1-
StrepII, StrepII-LSM14B, StrepII-UPF3B, StrepII-NF2, and StrepII-DEPDC1, a
coupled transcription/translation system (Promega) was used in combination
withS35-methionine (HARTMANN-Analytic) according to manufacturer’s
instructions. Following the reaction, each sample was supplied with 10 mM IAA
and 10 µM MG132 and incubated for an additional 30 min on ice. Recombinant
His- and His-AviTag-UBB, His-UBE2C, His-UBE2R1, His-Ubc9, His-AviTag-
SMT3, GST-BirA, N-terminal StrepII-CCNB1 (aa 1–86) and PTTG1-StrepII were
expressed in logarithmically growing E. coli BL21(DE3) in lysogeny broth (LB)
media supplemented with 50 µg/ml kanamycin (Sigma-Aldrich). Expression was
induced with 0.5 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG, VWR) at
26 °C for 6 h. Recombinant GST-UBA1, strepII-UPF3B, strepII-LSM14B, and GST-
TEV protease were expressed in E. coli BL21(DE3) Rosetta 2 in LB media sup-
plemented with 50 µg/ml kanamycin and 35 µg/ml chloramphenicol (Sigma-
Aldrich). Expression was induced by 0.3 mM IPTG at 18 °C overnight. Following
expression cells were harvested by centrifugation and re-suspended in BEN Buffer
(50 mM Tris-HCl pH 8, 250 mM NaCl, 2.5 mM MgCl2, 5 mM β-mercaptoethanol,
10 mM imidazole (Sigma-Aldrich), 1 mM PMSF, 5% glycerol) for Ni-NTA pur-
iﬁcation, in BEG buffer (50 mM Tris-HCl pH 8, 250 mM NaCl, 2.5 mM MgCl2,
1 mM DTT, 1 mM PMSF, 5% glycerol) for GST puriﬁcation, in BES buffer (30 mM
Tris-HCl pH= 8, 150 mM NaCl, 2.5 mM MgCl2, 1 mM DTT, 0.05% Tween 20,
1 mM PMSF) for StrepII puriﬁcation, or in BEU buffer (50 mM Tris-HCl pH 8,
150 mM NaCl, 10 mM MgCl2, 0.2 mM DTT, 1 mM PMSF, 5% glycerol) for UBA1
puriﬁcation. Cells were lysed by sonication and cleared by centrifugation at
50,000 × g on 4 °C for 1 h. His-tagged proteins were immobilized on Ni-NTA
(Merck Millipore), washed and eluted in SB buffer (30 mM HEPES-NaOH pH 7.5,
150 mM NaCl, 2.5 mM MgCl2, 1 mM DTT, 10% Glycerol) supplemented with 100
mM, 150 mM, and 250 mM imidazole in a sequential order. Following elution, the
proteins were re-buffered into SB buffer without imidazole. GST-tagged proteins,
except for GST-UBA1, were bound to Glutathione Sepharose 4B (GE Healthcare)
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beads, washed and eluted in 50 mM Tris-HCl pH 8, 100 mM NaCl, 1 mM DTT,
0.5 mM EDTA, 10 mM reduced L-Glutathione, and re-buffered into SB buffer.
StrepII-tagged proteins were bound to Strep-Tactin Superﬂow (IBA Life Sciences),
washed, eluted in Buffer E (IBA Life Sciences) and re-buffered into SB buffer.
Active GST-UBA1 was puriﬁed according to a modiﬁed protocol from Hershko
and colleagues79 using bioUBB immobilized on NeutrAvidin beads (Thermo-
ﬁsher). Brieﬂy, cleared lysates of cells expressing GST-UBA1 were supplemented
with 5 mM ATP and passed on the bioUBB column to covalently link GST-UBA1
to ubiquitin via a thioester bond on its active site. Subsequently, the column was
washed sequentially with buffer 1 (50 mM Tris-HCl pH= 8, 10 mM MgCl2, 0.2
mM DTT), buffer 2 (50 mM Tris-HCl pH= 8, 1 M KCl, 0.2 mM DTT) and buffer
3 (50 mM Tris-HCl, pH= 8). Active GST-UBA1 was eluted by 10 mM DTT in EB
buffer (50 mM Tris-HCl pH= 8, 10% Glycerol) and re-buffered into SB buffer.
Puriﬁed N-terminal CCNB1 and PTTG1 were labeled by IRDye 680RD or IRDye
800CW maleimides (Li-Cor) according to the manufacturers’ instructions.
Recombinant UBE2D1 was a kind gift of Jonathon Pines (ICR London, UK).
UBB and SMT3 biotinylation. For in vitro biotinylation puriﬁed His-AviTag-UBB
and His-AviTag-SMT3KGG were re-buffered into BRB buffer (50 mM bicine-NaOH
pH= 8.3, 10 mM Mg(OAc)2). Then 40 µM His-AviTag-UBB or His-AviTag-SMT3
were mixed together with biotin (10 mM), GST-BIRA (4.5 µg enzyme/1 nmol UBB)
and ATP (10 mM) in BRB buffer and incubated for 3 h at 30 °C. Following the
reaction biotinylated His-AviTag-UBB and His-AviTag-SMT3 were puriﬁed from
the reaction mix via the His-tag under standard Ni-NTA puriﬁcation conditions
(see Supplementary Figure 1).
E2 charging reactions. For E2 charging, recombinant GST-UBA1 (280 nM),
UBE2R1 (8.5 µM), UBE2D1 (13.73 µM) or UBE2CK119R or UBE2CC114S (11.5 µM)
and bioUBB (8.30 µM) were mixed together in RBU (50 mM HEPES pH= 7.5, 100
mM KCl, 2.5 mM MgCl2) in a 25 µl reaction, pre-incubated for 15 min at room
temperature (RT). Charging was initiated by the addition of 2 mM ATP and
incubation for 20 min at 20 °C. For Ubc9 charging, 100 nM AOS1-UBA2 (Boston
Biochem), Ubc9 WT (12.75 µM) and bioSMT3 (8.2 µM) were mixed together in
RBS (20 mM HEPES pH= 7.5, 110 mM KCl, 2.5 mM MgCl2) in a 25 µl reaction,
pre-incubated for 15 min at RT. Charging was initiated by the addition of 5 mM
ATP and incubation for 35 min at 30 °C. For SDS-PAGE analyses reactions were
stopped by LDS-sample buffer without DTT or with 50 mM DTT and the DTT
containing samples were boiled at 95 °C for 5 min. For subsequent in extracto or
E2~dID assays charging reactions were treated with 10 mM fresh IAA for 30 min
on ice before use.
In vitro ubiquitination assays. APC/C was puriﬁed from extracts using mono-
clonal anti-ANAPC4 or anti-HA antibodies (see Supplementary Data 7 for dilu-
tions and catalogue numbers of all antibodies used in this study). Brieﬂy 400 µg
antibodies were coupled to 1 ml Protein G Dynabeads (Thermo-Fisher) according
to the manufacturer’s instructions and equilibrated in MEB buffer. For in vitro
ubiquitination assays, ANAPC4 antibody-beads were mixed with cell extracts at a
1 µg antibody to 166 µg extract ratio for 2 h on 4 °C on a wheel. Subsequently,
beads were washed 3× with MEB buffer and 2× with URB buffer (30 mM HEPES-
NaOH pH 7.5, 175 mM NaCl, 6 mM MgCl2, 0.05% Tween-20, 1 mM DTT, 5%
Glycerol), re-suspended in URB, and 2–3 µg antibody-beads were combined with
enzymes and substrates in 13–15 µl reactions. A reaction contained 46.5–53.76 nM
GST-UBA1, 341.9–394.5 nM UBE2C WT or K119R, 115.9–133.8 nM UBE2S,
36.7–42.4 µM His-UBB, 2–2.3 mM ATP and 10.1–11.7 mM Phosphocreatine (PC),
2.3–2.6 µM creatine kinase (CK) and 1 µM bovine serum albumin (BSA). For
detection, substrates were either IRDye-labelled (see above) or StrepII-tagged for
Western blot analysis. Reactions were incubated for 45 min at 30 °C, stopped by the
addition of LDS-sample buffer (Thermo-Fisher) containing 50 mM DTT, followed
by separation of proteins on SDS-PAGE and detection of ﬂuorescently-labeled
substrates by infrared scanning (Li-Cor) or Western blot using the indicated
antibodies (see Supplementary Data 7 for dilutions and catalogue numbers). For
in vitro ubiquitination reactions shown in Supplementary Figure 1, UBE2C char-
ging reactions (see above) treated with 10 mM IAA were used as a source of
UBE2C~ubiquitin conjugates.
In extracto ubiquitination assays and E2~dID. To deplete APC/C from extracts
ANAPC4 or HA (mock treatment) antibody-beads were mixed with cell extracts
(10 µg antibody/ 1000 µg extract) and incubated for 30 min at 4 °C on a wheel. To
ensure efﬁcient depletion, the process was repeated 3× more times with fresh
antibody-beads. Mock or ANAPC4-depleted extracts were supplemented with
ﬂuorescently-labeled N-terminal CCNB1 IRDye-680, charging reactions (see
above) in a 1 reaction/60 µg extract ratio, incubated for 30 min at 30 °C, stopped by
the addition of LDS-sample buffer containing 50 mM DTT and analyzed by SDS-
PAGE and ﬂuorescent infrared scanning (Li-Cor). Ubiquintinated proteins from in
extracto assays with 35S-methionin (1 charging reaction/100 µg extract) labeled
PTTG1, LSM14B, NF2, UPF3B, and DEPDC1 were puriﬁed from reactions with
Dynabeads MyOne Streptavidin T1 beads (Thermoﬁsher), washed 2× with buffer 1
(100 mM Tris-HCl pH= 8, 8 M urea), 1× with buffer 2 (100 mM Tris-HCl pH= 8,
8 M urea) and 2× with RIPA buffer (25 mM Tris-HCl pH= 8, 150 mM NaCl, 0.1%
sodium dodecyl sulfate, 0.5% sodium dodecyl sulfate (SDS), 1% Triton X-100),
eluted with LDS-sample buffer containing 50 mM DTT at 96 °C for 10 min and
analyzed by SDS-PAGE and autoradiography on a phosphorimager (FUJIFILM,
FLA-3000). E2~dID assays processed for analysis by mass spectrometry were
performed as described above but scaled up (10 mg extract per condition at 10 mg/
ml supplied with 35 charging reactions, which is equivalent to a 24.4-fold excess of
recombinant UBE2CK119R/CS over the endogenous UBE2C, (see Supplementary
Figure 2b). After incubation at 30 °C for 30 min 100 µl of equilibrated NeutrAvidin
beads were added, followed by incubation for 30–45 min at 4 °C on a wheel, 3 ×
washing with WB1 (100 mM Tris-HCl pH= 8, 8 M Urea, 0.5% SDS), 3 × washing
with WB2 (100 mM Tris-HCl pH= 8, 4 M Urea, 0.5% SDS), 3x washing WB3 (D-
PBS, 0.5% SDS), 3 × washing with WB4 (100 mM Triethylammonium bicarbonate
(TEAB) pH= 8.5, 8 M Urea), 2× washing with WB5 (100 mM TEAB pH= 8.5,
4 M Urea) and 2 × washing with WB6 (100 mM TEAB pH= 8.5). For Western
blot analysis, the beads were eluted with LDS-sample buffer containing 50 mM
DTT and boiled on 96 °C for 10 min. For mass spectrometry (MS) analysis, the
beads were re-suspended in an equal volume of digestion buffer (100 mM TEAB
pH= 8.5, 10 mM tris(2-carboxyethyl)phosphine (TCEP), 10 mM IAA), incubated
at RT for 60 min, supplied with 2 µg MS grade Trypsin (Thermoﬁsher) and
incubated overnight at 37 °C. The digested peptides were ﬁltered in C8 ﬁlter-tip
(in-house made) to remove possible magnetic beads, dried in a SpeedVac and
labelled with TMT10plex as instructed by the manufacturer (Thermo Fisher).
Labeled peptides were mixed, dried in a SpeedVac and fractionated on a U3000
HPLC system (Thermo Fisher) using an XBridge BEH C18 column (2.1 mm id ×
15 cm, 130 Å, 3.5 µm, Waters) at pH= 10, and a ﬂow rate at 200 µl/min in 30 min
linear gradient from 5–35% acetonitrile/NH4OH. The fractions were collected at
every 30 sec into a 96-well plate by columns, concatenated by rows to 8 pooled
fractions and dried in the SpeedVac.
Co-immunoprecipitation and western blotting. APC/C was immunoprecipitated
(IP) from extracts using custom mouse monoclonal ANAPC3 (Supplementary
Figure 5b) or commercial (Bethyl) rabbit polyclonal anti-ANAPC3 antibodies
(Fig. 4d). Control (ctr) immunoprecipitations (IP) were performed with mouse
monoclonal anti-FLAG or non-speciﬁc rabbit IgG antibodies (see Supplementary
Data 7 for dilutions and catalogue numbers). Brieﬂy 400 µg antibodies were cou-
pled and crosslinked to 1 ml Protein G Dynabeads (Thermo-Fisher) according to
the manufacturer’s instructions. For IP, Flag and ANAPC3 antibody-beads were
equilibrated in MEB buffer and added to cell extracts at a 16 µg antibody to 1000 µg
extract ratio and incubated for 2 h 4 °C on a wheel. Subsequently, beads were
washed 6× with MEB buffer and then re-suspended in 1X LDS-sample buffer. For
IPs with rabbit polyclonal anti-ANAPC3 antibodies, 1 µg ctr or ANAPC3 anti-
bodies were added to 1000 µg extract for 1 h at 4 °C on a wheel. Then 10 µl MEB-
equilibrated Protein G Dynabeads were added for 1 h, followed by 6 washes in
MEB buffer and resuspension in 1× LDS-sample buffer. Samples were eluted from
beads by boiling at 65 °C for 5 min, separated by SDS-PAGE on Bis-Tris 4–12%
gradient gels in MES or MOPS buffer. Western blotting was performed in 20%
ethanol/MOPS buffer (all Thermo Fisher Scientiﬁc) in a Mini Trans-Blot electro-
phoretic cell (Bio-Rad), and detected with the indicated antibodies (see Supple-
mentary Data 7 for dilutions and catalogue numbers). Uncropped scans of blots
presented in the main ﬁgures are provided in Supplementary Figure 6 within
the Supplementary Information.
Yeast methods and Def1-HA immunoprecipitation. Yeast Media and genetic
manipulations were done using standard methods. The Def1-HA strain has the
S288C background. Anti-HA immunoprecipitations were performed using glass-
bead lysates from 100 OD yeast cells grown in YPD, in a buffer containing 50 mM
TrisCl pH 7.6. 150 mM NaCl, 1 mM MgCl2, 1 mM EGTA, supplemented with 1
mM PMSF, yeast protease inhibitor cocktail (Sigma P8215)) and 25 mM NEM for
2 h at 4 °C using the mouse anti-HA antibody (Sigma HA-7, H3663) and Pan-
mouse Dynabeads (Invitrogen). Beads were washed 4× with the same buffer at RT
and once with 105 NH4OH solution pH= 11 for 30 min at 37 °C. HA-Def1 was
ﬁnally eluted by adding 2× Laemmli buffer and heating for 10 min at 90 °C.
Western blots were performed using the same mouse HA-7 antibody or the anti-
Smt3 antibody (gift from F. Melchior).
Ubiquitin remnant peptide enrichment. Cell pellet was lysed in 5 mM IAA in 5%
SDS/100 mM TEAB, and processed by ultrasonic probe and heated at 90 °C for 10
min, then processed again by ultrasonic probe. Lysate was cleared by centrifuge at
16,000 × g for 15 min. Protein concentration was measured by Pierce 660 nm
Protein Assay (Thermo), then aliquoted at 5 mg each. After reduced by 10 mM
TCEP at 56 °C for 15 min and alkylated by 10 mM IAA at RT for 30 min, proteins
were precipitated by chloroform/methanol. 1 ml of 100 mM TEAB was added to
the protein pellet and the mixture was left in ultrasonic bath for up to 30 s to
disperse the pellet well. For two of three 5 mg-aliquot of each sample, 20 µg of Lys-
C (Wako) was added and digested for 2 h at 30 °C. Then to all 5 mg-aliquot
samples, 80 µg trypsin (Pierce) was added and incubated at 37 °C for 2 h. Another
80 µg trypsin was added and incubated for further 15 h. The digest was then heated
at 70 °C for 10 min then dried in SpeedVac.
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For ubiquitin-peptide enrichment, 15 mg of the above digest was taken for each
condition (+APC/C and −APC/C): two of 5 mg-aliquot with Lys-C pre-treated,
and one without. (Based on the charge distribution map of the LC-MS/MS analysis,
the digestion efﬁciency was the same with or without Lys-C pre-treatment.) We
analyzed three replicates for each condition (6 samples in total). The enrichment
was performed in three consecutive IP steps: twice with PTMScan® Ubiquitin
branch motif (K-ε-GG) immunoafﬁnity beads (Catalogue #5562) from Cell
Signalling Technology (CST), followed by enrichment with the GX41 antibody
(Lucerna Technologies). Brieﬂy, in the 1st IP, 1500 µl IAP buffer (50 mM MOPS
(pH= 7.2), 10 mM sodium phosphate and 50 mM NaCl), CST) was added to each
sample to dissolve the peptides with the assistance of ultrasonic bath up to 30 s, and
then the mixture was centrifuged at 16,000 × g to remove any precipitation. To the
cleared peptide digest, 1 vial of PBS pre-washed (4 × ) CST antibody-beads were
added, and incubated with rotation for 2 h at room temperature (RT). The mixture
was centrifuged at 2000 × g for 30 s and the supernatant was collected to perform
the 2nd IP by incubation with another vial of the CST antibody-beads overnight at
4 °C, and then at RT for another 2 h, and centrifuged as above. Supernatant was
collected again, and 100 µg of GX41 antibody and 150 µl of Protein G-Dynabeads
(Thermo) were added and incubated at RT for 2 h before the supernatant was
discarded. Each IP’s ubiquitin-peptide enriched beads (2× by CST and 1× GX41)
were washed twice with IAP buffer, twice with PBS and once with cold HPLC
water, then incubated twice with 55 µl of 0.15% TFA for 10 min to eluted the
ubiquitin-peptides. The eluates from the same sample were pooled and desalted in
a home-made SDB-XC (EmporeTM, 3M) tips to remove antibody in the sample,
and then dried in SpeedVac, labeled by TMT10plex, pooled and SpeedVac dried
again before HpH fractionation and concatenated to 8 fractions.
LC–MS/MS analysis. For peptides from E2~dID experiment, the LC-MS/MS
analysis were performed on the Orbitrap Fusion Tribrid mass spectrometer cou-
pled with U3000 RSLCnano UHPLC system. Both instrument and columns used
below are from Thermo Fisher. The peptides were ﬁrst loaded to a PepMap C18
trap (100 µm i.d. × 20 mm, 100 Å, 5 µm) for 10 min at 10 µl/min with 0.1% FA/
H2O, then separated on a PepMap C18 column (75 µm i.d. × 500 mm, 100 Å, 2 µm)
at 300 nl/min and a linear gradient of 4–28% ACN/0.1%FA in 180 min/cycle at 210
min for each fraction. The data acquisition used the SPS10-MS3 method with Top
Speed at 3 s per cycle time. The full MS scans (m/z 380–1500) were acquired at
120,000 resolution at m/z 200 with a lock mass at 445.12003, and the AGC was set
at 4e5 with 50 ms maximum injection time. Then the most abundant multiply-
charge ions (z= 2–6, above 5000 counts) were subjected to MS/MS fragmentation
by CID (35% CE) and detected in ion trap for peptide identiﬁcation. The isolation
window by quadrupole was set m/z 1.0, and AGC at 1e4 with 35 ms maximum
injection time. The dynamic exclusion window was set ± 10 ppm with a duration
at 40 s, and only single charge status per precursor was fragmented. Following each
MS2, the 10-notch MS3 was performed on the top 10 most abundant fragments
isolated by Synchronous Precursor Selection (SPS). The precursors were frag-
mented by HCD at 65% CE then detected in Orbitrap at m/z 100–500 with 50 K
resolution to for peptide quantiﬁcation data. The AGC was set 1e5 with maximum
injection time at 105 ms.
Ubiquitin remnant peptide enrichment analyses were performed on a Orbitrap
Fusion Lumos, and the analysis method was MS2 based at very similar conditions
to the above but with several modiﬁcations: The gradient was 90 min/120 min
cycle. Peptide ions with charge at 3–6 were selected for HCD fragmentation at 38%
collision energy. The isolation width was set 0.7 Da. The fragment ions were
detected in Orbitrap with 30 K resolution, and the AGC was set 50,000 with
maximum injection time at 100 ms.
Data analysis. The LC-MS/MS data were processed in Proteome Discoverer 2.1
(Thermo Fisher Scientiﬁc) using the SequestHT search engine to search against the
reviewed Uniprot protein database of Homo sapiens (20,238 entries, Swiss-prot), or
Saccharomyces cerevisiae (7904 entries, Swiss-Prot), plus the in-house contaminate
database. The precursor mass tolerance was set at 20 ppm and the fragment ion
mass tolerance was set at 0.5 Da. Spectra were searched for fully tryptic peptides
with maximum 2 miss-cleavages. Carbamidomethyl at Cys was set as static
modiﬁcations, and the dynamic modiﬁcations included N-acetylation (Protein N-
terminus), Deamidation (N, Q), Oxidation (M), TMT6plex (Peptide N-terminus,
K), and GGTMT6plex (+ 343.2059) (K). Note, we used a SMT3KGG mutant13 to
obtain a shorter SUMO remnant. Peptides were validated by Percolator with q-
value set at 0.05 for the Decoy database search. The search result was ﬁltered by the
Consensus step where the protein FDR was set at 0.01 (strict) and 0.05 (relaxed).
The TMT10plex reporter ion quantiﬁer used 20 ppm integration tolerance on the
most conﬁdent centroid peak at the MS3 level. Both unique and razor peptides
were used for quantiﬁcation. Peptides with average reported S/N > 3 were used for
protein quantiﬁcation. Only master proteins were reported (Supplementary Data 1,
UBE2C E2~dID and Supplementary Data 4, Ubc9 E2~dID).
Scaled TMT abundances were used to generate heat maps (Morpheus, Broad
Institute, USA) and calculate thresholds as indicated in the main text and the
legends of Supplementary Data 1 and 4. Modiﬁcation with ubiquitin and SUMO
according to BioGRID1 and APC/C degrons prediction according to ProViz45
accepting only degrons with a disorder score of > 0.5. Reproducibility between data
sets was determined according to Pearson correlation calculated by R. Visualization
of data as a Venn diagram was done with InteractiVenn80. To generate a unbiased
reference list to compare the sensitivity and speciﬁcity of E2~dID with alternative
approaches, the mitotic and mitotic exit substrates (human and mouse and their
isoforms) of APC/C listed at ProViz45 were extracted and only substrates with
degrons veriﬁed by mutation or deletions experiments were accepted
(Supplementary Data 2, including references). Candidate substrates suggested by
co-regulation proteomics33 were compiled according to the authors thresholding
(1st percentile) combining the hits of reference clusters 1–6. Candidate substrates
suggested by the mitotic exit proteome46 included all proteins designated as C- and
M-speciﬁc. Candidate substrates suggested by protein microarrays23,24 included all
proteins designated by the authors as positive hits. The reference list of
experimentally-veriﬁed Siz1 and Siz2 substrates was assembled from the literature
(Supplementary Data 5, including references). Sensitivity is deﬁned by how many
candidates were identiﬁed from the reference list (in %). Speciﬁcity is deﬁned by
how many of all hits proposed by each study are part of the reference list (in %).
Statistical methods. Prism 6.0 (Graphpad) and RStudio were used for statistics
and to create graphs. All data are representative of at least three independent
repeats if not otherwise stated. The notation n refers to the number independently
performed experiments representative of the data shown in the ﬁgures. Signiﬁcance
of the data shown in Fig. 3e was determined by a Wilcoxon rank sum test. No
randomization or blinding was used in this study.
Data availability
Generated plasmids and cell lines are available from the corresponding author
upon request. The mass spectrometry proteomics data have been deposited to the
ProteomeXchange Consortium via the PRIDE partner repository with the dataset
identiﬁer PXD008624. All other data supporting the ﬁndings of this study are
available from the corresponding author on reasonable request.
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